Characterization of functional assays of multidrug resistance P-glycoprotein transport activity

Leukemia

Volumn 11, Issue 7, 1997, Pages 1131-1137

  Bosch, I ^a   Crankshaw, C L ^b   Piwnica Worms, D ^b   Croop, J M ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

MDR; Multidrug resistance; P glycoprotein

Indexed keywords

CARBOCYANINE; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RHODAMINE 123; TRITIUM; VALSPODAR; VINBLASTINE;

ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RADIOASSAY;

EID: 0030795841     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400695     Document Type: Article

References (20)

1. Fisher CA, Sikic BI (eds). Drug Resistance in Clinical Oncology and Hematology. WB Saunders: Philadelphia, 1995. Hematology/Oncology Clinics of North America, vol. 9.
2. Bosch I, Croop JM. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996; 1288: F37-F54.
3. Gottesman M, Hrycyna C, Schoelein P, Germann U, Pastan I. Genetic analysis of the multidrug transporter. Ann Rev Genet 1995; 29: 607-649.
4. Childs S, Ling V. The MDR superfamily of genes and its biological implications. In: DeVita V, Hellman S, Rosenberg S (eds). Important Advances in Oncology. Lippincott: Philadelphia, 1994, pp 21-36.
5. Roninson IB (ed). Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press: New York, 1991.
6. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-199.
7. Zhang X, Collins KI, Greenberger LM. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J Biol Chem 1995; 270: 5441-5448.
8. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-3020.
9. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
10. Rao V, Chiu M, Kronauge J, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of Technetium-99m-Sestamibi. J Nuclear Med 1994; 35: 510-515.
11. Piwnica-Worms D, Rao W, Kronauge JF, Croop JM. Characterization of multidrug resistance P-glycoprotein transport function with an organothechetium cation. Biochemistry 1995; 34: 12210-12220.
12. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 1979; 39: 2070-2076.
13. Arceci R, Stieglitz K, Bierer K. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992; 80: 1528-1536.
14. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991; 77: 348-354.
15. Dalton WS, Durie BGM, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986; 46: 5125-5130.
16. Kartner N, Evernden-Porelle D, Bradley C, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820-823.
17. Gaveriaux C, Boesch D, Boelsterli JJ, Bollinger P, Eberle MK, Hiestand P, Payne T, Traber R, Wenger R, Loor F. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Br J Cancer 1989; 60: 867-871.
18. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D. Analysis of the interactions of SDZ PSC 833 ([3′-keto-bmt1]-val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 1995; 7: 603-610.
19. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(l) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
20. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharm 1994; 46: 627-638.